Shanu Modi
YOU?
Author Swipe
View article: Characterization of the Safety Profile of Trastuzumab Deruxtecan by Dose: A Pooled Analysis Across DESTINY Studies
Characterization of the Safety Profile of Trastuzumab Deruxtecan by Dose: A Pooled Analysis Across DESTINY Studies Open
Background Trastuzumab deruxtecan (T-DXd), an approved human epidermal growth factor receptor 2 (HER2)–directed antibody–drug conjugate, may cause treatment-emergent adverse events (TEAEs), most commonly gastrointestinal and hematologic TE…
View article: Evaluating post-T-DXd treatment strategies in HER2-positive metastatic breast cancer
Evaluating post-T-DXd treatment strategies in HER2-positive metastatic breast cancer Open
Our study indicates that patients emerge from T-DXd treatment with highly refractory disease. These findings highlight the urgent need for optimized treatment strategies and novel therapeutic options for this patient population.
View article: Trastuzumab Deruxtecan (T-DXd) Resistance via Loss of HER2 Expression and Binding
Trastuzumab Deruxtecan (T-DXd) Resistance via Loss of HER2 Expression and Binding Open
T-DXd is clinically beneficial in HER2 positive and HER2 low metastatic breast cancer. However, therapeutic resistance emerges over time in most patients, with poorly defined resistance mechanisms. Through a molecular characterization of p…
View article: Neoadjuvant trastuzumab deruxtecan alone or followed by paclitaxel, trastuzumab, and pertuzumab for high-risk HER2-positive early breast cancer (DESTINY-Breast11): a randomised, open-label, multicentre, phase III trial
Neoadjuvant trastuzumab deruxtecan alone or followed by paclitaxel, trastuzumab, and pertuzumab for high-risk HER2-positive early breast cancer (DESTINY-Breast11): a randomised, open-label, multicentre, phase III trial Open
Neoadjuvant T-DXd-THP demonstrated statistically significant and clinically meaningful pCR benefit and improved safety versus ddAC-THP.
View article: Cardiac Safety of Reduced Cardiotoxicity Surveillance During HER2-Targeted Therapy
Cardiac Safety of Reduced Cardiotoxicity Surveillance During HER2-Targeted Therapy Open
Reduced CTRCD surveillance every 6 months is safe and feasible for patients at low risk for CTRCD and may be an appropriate strategy to consider during non-anthracycline HER2-targeted treatment regimens.
View article: Cardiovascular implications of metabolic dysfunction-associated fatty liver disease and type 2 diabetes mellitus: A meta-analysis
Cardiovascular implications of metabolic dysfunction-associated fatty liver disease and type 2 diabetes mellitus: A meta-analysis Open
BACKGROUND Metabolic dysfunction-associated fatty liver disease (MAFLD) and type 2 diabetes mellitus (T2DM) are independent risk factors for the development of cardiovascular disease (CVD) and an exaggerated CVD risk is expected when both …
View article: Patient-reported outcomes from DESTINY-Breast04: trastuzumab deruxtecan versus physician’s choice of chemotherapy in patients with HER2-low mBC
Patient-reported outcomes from DESTINY-Breast04: trastuzumab deruxtecan versus physician’s choice of chemotherapy in patients with HER2-low mBC Open
Background The phase 3 DESTINY-Breast04 trial demonstrated superior efficacy and acceptable safety with trastuzumab deruxtecan (T-DXd) vs physician’s choice of chemotherapy in previously treated patients with human epidermal growth factor …
View article: Treatment patterns and outcomes in HER2-low metastatic breast cancer patients previously treated with chemotherapy: a US real-world cohort study
Treatment patterns and outcomes in HER2-low metastatic breast cancer patients previously treated with chemotherapy: a US real-world cohort study Open
These data highlight the unmet clinical needs of patients with HER2-low mBC by characterizing the treatment patterns and poor outcomes in this population on the current standard of care.
View article: Local Therapy for Isolated Central Nervous System Progression Among Patients Receiving Antibody-Drug Conjugate Therapy
Local Therapy for Isolated Central Nervous System Progression Among Patients Receiving Antibody-Drug Conjugate Therapy Open
To the best of our knowledge, this is the first clinical report of outcomes using the guideline-recommended approach of local therapy for isolated brain relapse among patients receiving ADCs. Local therapy may delay the need for next line …
View article: Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer: a plain language summary of the DESTINY-Breast04 study
Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer: a plain language summary of the DESTINY-Breast04 study Open
What is this summary about? This is a summary of the publication about the DESTINY-Breast04 study, which was published in the New England Journal of Medicine in July 2022. The study included 557 adults with advanced or metastatic, HER2-low…
View article: Invasive disease-free survival and brain metastasis rates in patients treated with neoadjuvant chemotherapy with trastuzumab and pertuzumab
Invasive disease-free survival and brain metastasis rates in patients treated with neoadjuvant chemotherapy with trastuzumab and pertuzumab Open
Patients with HER2(+) early breast cancer (EBC) receiving neoadjuvant systemic therapy (NAST) have poorer outcomes if they have residual disease (RD). We analyzed IDFS and brain metastasis (BM) rates in patients with HER2(+) EBC treated wi…
View article: Predictors of response to CDK4/6i retrial after prior CDK4/6i failure in ER+ metastatic breast cancer
Predictors of response to CDK4/6i retrial after prior CDK4/6i failure in ER+ metastatic breast cancer Open
After disease progression on endocrine therapy (ET) plus a CDK4/6 inhibitor, there is no standardized sequence for subsequent treatment lines for estrogen receptor positive (ER+) metastatic breast cancer (MBC). CDK4/6i retrial as a treatme…
View article: Trastuzumab deruxtecan versus treatment of physician’s choice in previously treated Asian patients with HER2-low unresectable/metastatic breast cancer: subgroup analysis of the DESTINY-Breast04 study
Trastuzumab deruxtecan versus treatment of physician’s choice in previously treated Asian patients with HER2-low unresectable/metastatic breast cancer: subgroup analysis of the DESTINY-Breast04 study Open
Background In the global phase 3 DESTINY-Breast04 study (NCT03734029), the anti-human epidermal growth factor 2 (HER2) antibody–drug conjugate trastuzumab deruxtecan (T-DXd) demonstrated a statistically significant improvement in progressi…
View article: Formulation and Evaluation of Metoclopramide Orodispersible Tablet
Formulation and Evaluation of Metoclopramide Orodispersible Tablet Open
In the study all the formulation were subjected to physical parameters of tablets, like hardness, friability, weight variation, drug content of Metoclopramide hydrochloride. All the formulations resulted in acceptable limit except formulat…
View article: 267MO Pooled analysis of trastuzumab deruxtecan (T-DXd) retreatment (RTx) after recovery from grade (Gr) 1 interstitial lung disease/pneumonitis (ILD)
267MO Pooled analysis of trastuzumab deruxtecan (T-DXd) retreatment (RTx) after recovery from grade (Gr) 1 interstitial lung disease/pneumonitis (ILD) Open
T-DXd, an approved therapy for multiple cancers, carries a risk of interstitial lung disease/pneumonitis (ILD) which may have fatal outcomes if not appropriately identified and managed. Management guidelines require interrupting T-DXd for …
View article: 188P A health-related quality-of-life (HRQoL) analysis from DESTINY-Breast04: Trastuzumab deruxtecan (T-DXd) vs capecitabine (CAP) in patients (Pts) with hormone receptor-positive (HR+), HER2-low metastatic breast cancer (mBC)
188P A health-related quality-of-life (HRQoL) analysis from DESTINY-Breast04: Trastuzumab deruxtecan (T-DXd) vs capecitabine (CAP) in patients (Pts) with hormone receptor-positive (HR+), HER2-low metastatic breast cancer (mBC) Open
In DESTINY-Breast04 (NCT03734029), 494 pts were assigned to T-DXd or treatment of physician's choice (TPC), including CAP. Progression-free survival and overall survival favored T-DXd vs TPC in pts with HR+, HER2-low (immunohistochemistry …
View article: Phosphorylation-Driven Epichaperome Assembly: A Critical Regulator of Cellular Adaptability and Proliferation
Phosphorylation-Driven Epichaperome Assembly: A Critical Regulator of Cellular Adaptability and Proliferation Open
The intricate protein-chaperone network is vital for cellular function. Recent discoveries have unveiled the existence of specialized chaperone complexes called epichaperomes, protein assemblies orchestrating the reconfiguration of protein…
View article: First-in-Human Evaluation of Site-Specifically Labeled<sup>89</sup>Zr-Pertuzumab in Patients with HER2-Positive Breast Cancer
First-in-Human Evaluation of Site-Specifically Labeled<sup>89</sup>Zr-Pertuzumab in Patients with HER2-Positive Breast Cancer Open
Radioimmunoconjugates targeting human epidermal growth factor receptor 2 (HER2) have shown potential to noninvasively visualize HER2-positive tumors. However, the stochastic approach that has been traditionally used to radiolabel these ant…
View article: Trastuzumab deruxtecan in patients with human epidermal growth factor receptor 2–expressing salivary gland carcinoma: a pooled analysis of two phase I studies
Trastuzumab deruxtecan in patients with human epidermal growth factor receptor 2–expressing salivary gland carcinoma: a pooled analysis of two phase I studies Open
Background HER2-expressing salivary gland carcinoma (SGC) is associated with poor prognosis. Trastuzumab deruxtecan (T-DXd, DS-8201) has shown evidence of antitumor activity for several HER2-expressing solid tumors in multiple studies. Thi…